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Twenty-ﬁve primary retinoblastoma tumours were analysed by real-time quantitative polymerase chain reaction to determine
the genomic copy number of the N-MYC gene (2p24) relative to the copy number for REL, B2M, ALB, AF10 and MLL.
Twenty-one of these tumours were shown by Comparative Genomic Hybridization to contain variable copy number increases
of chromosomal material mapping to 2p. High level ampliﬁcation (430-fold) of N-MYC was found in three tumours, none of
which showed adverse histological features and all patients are surviving at between 54 and 108 months post enucleation.
Furthermore, the three tumours associated with metastasis and adverse patient outcome showed normal N-MYC copy
number. Although high level ampliﬁcation of N-MYC is an unfavourable prognostic indicator in neuroblastoma, these data
show no evidence of a correlation between ampliﬁcation of N-MYC and adverse outcome in retinoblastoma.
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Retinoblastoma (Rb) is an intraocular malignancy affecting young
children with a frequency of one per 20000 live births (Knud-
son, 1971). Mutation of the RB1 tumour suppressor gene,
located at chromosome 13 band q14, is essential to the patho-
genesis of Rb. In hereditary cases (40–45% of cases) there is
a germline mutation of RB1, thereby conferring predisposition,
and the second allele is inactivated by somatic mutation. This
‘two hit’ mechanism was ﬁrst hypothesised by Knudson (Knud-
son, 1976) and later substantiated following cloning of RB1
(Friend et al, 1986). In patients with germline mutations, bilat-
eral Rb tumours usually develop and patients have an
increased risk of secondary cancers, in particular osteosarcoma
and soft tissue sarcoma (Draper et al, 1986; Roarty et al,
1988). In the sporadic unilateral Rb tumours, both RB1 muta-
tions are required in the same somatic cell to initiate tumour
formation. The risk factors for the development of sporadic Rb
are not clear but it has been suggested that exposure to human
papilloma viruses may play a role (Orjuela et al, 2000). A variety
of chromosomal abnormalities have been reported in Rb
tumours (Benedict et al, 1983; Squire et al, 1985; Mitelman,
2001), including frequent gains of 6p and 1q, although the
impact of these additional events on tumorigenesis and prognosis
has not been thoroughly investigated. A correlation between gain
of 6p and the most malignant behaviour in Rb has been
proposed (Oliveros and Yunis, 1995) and a relationship between
N-MYC ampliﬁcation, higher proliferation index (PI), advanced
tumour stage and poor clinical outcome was suggested (Kim et
al, 1999). It is well recognised in haematological malignancies
and solid tumours, that a number of recurrent chromosomal
abnormalities have independent prognostic importance (Ferrando
and Look, 2000; Misra et al, 2000; Mrozek et al, 2000; Taylor et
al, 2000; Mrozek et al, 2001) and, in particular, ampliﬁcation of
N-MYC is known to be associated with adverse outcome in child-
hood neuroblastoma (George et al, 2001; Lastowska et al, 2001).
Retinoblastoma, like neuroblastoma, is thought to be a tumour of
neuroectodermal origin and it shares a very similar pattern of
metastasis to neuroblastoma, metastasising predominantly to bone,
bone marrow, nodes and central nervous system. N-MYC is also a
target for ampliﬁcation in childhood Rb but whether this represents
a molecular marker for the assessment of prognosis in this tumour
type is not known. Real-time quantitative polymerase chain reaction
(RQ–PCR) using the TaqMan system provides a rapid and sensitive
method for the analysis of gene dosage (Goff et al, 2000; Tajiri et al,
2001). There was considerable variation, by CGH, in the extent of
gain for 2p23–25 in these Rb tumours and thus RQ–PCR was used
to determine N-MYC copy number and this was correlated with
tumour histology and outcome.
MATERIALS AND METHODS
Tumour samples
Tumour samples were obtained following enucleation and DNA
extracted using Nucleon BACC kits (Amersham International
plc, UK) according to the manufacturer’s protocol. Twenty-one
tumour DNA samples were identiﬁed by CGH to show gain of
2p material and these were selected for RT–PCR analysis. In
addition, tumour DNA from a further four patients, including
three (056, 035, 048) from the poor histo-prognostic risk (PR)
category two of whom died, was analysed although none had
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www.bjcancer.comevidence for gain of 2p by CGH. Seven tumours were derived
from six bilaterally affected patients and two patients had a posi-
tive family history (one bilateral and one unilateral case). The
histological risk, clinical details, CGH ﬁndings, treatment and
outcome are summarised in Tables 1 and 2. CGH was performed
using Vysis CGH kits (Vysis, Inc., France) according to the
recommended protocol. The risk factors were assigned according
to the criteria of Khelfaoui et al (1996) and the study was
approved by the East London and The City Health Authority
Research Ethics Committee.
Real-time quantitative polymerase chain reaction
(RQ–PCR)
RQ–PCR analysis was performed using the ABI Prism 7700
sequence detector system (Taqman assay). Primers for N-MYC
were chosen from intron 2 with the assistance of software Primer
Express version 1.0 (ABI/Perkin Elmer, Foster City, CA, USA).
The Accession Number for the sequence used was Y00664. The
N-MYC primer sequences were 5'–3' forward GAAGATATGTT-
TTGATTTTCATGCTTG, used at 300 nmol l
-1 and reverse TGT-
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Table 1 Comparison of clinical details and CGH ﬁndings in Rb tumours
Number of Tumours Poor histo risk Uni/Bil Family history Abn by CGH +2p Amp(2p2) [ampN-MYC] +1q +6p 716q 716
(n) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
CGH study (n=49) 27 65/35 8 96 31 12 57 69 27 12
RT–PCR study (n=25) 32 75/25 8 100 60 24 33 33 20 12
(47) [(100)]
Mairal et al, 2000 (n=24) 33 79/21 13 96 21 17 50 54 21 25
[(100)]
Herzog et al, 2001 (n=26) ND 100/0 0 65 12 4 38 44 31 4
Chen et al, 2001 (n=50) ND 72/28 ND 82 14 12 52 46 16 2
Poor histo risk=tumours with adverse histo-prognostic risk factors. Uni/Bil=Unilateral or Bilateral. Abn=Abnormal by CGH (+=gain; 7=loss). Amp(2p2)=ampliﬁcation by CGH;
[ampN-MYC=ampliﬁcation conﬁrmed by PCR]. ND=Not documented.
Table 2 CGH, RT–PCR, treatment and outcome of 25 Rb tumours
RQ–PCR (N-MYC)
Tumour Gains Losses Amp copy no* Treatment Status
PR group
004 1q,2p23pter,14q13q24 18p 6p 6.7 EA
008(L)
a 2p22p24,6p21 2.4 E+Ct A
017 2p23pter,9q34,12p12pter, 7p21p22,8q24,Xp22.3,Xq28 6p 2.3 E+Ct A
17q21qter,18q21q23,19p12pter
041 2q21pter,13q21qter,15q23qter 6q26qter 1p11q32,6p 2.3 EA
056 1p32qter,4p16,4q31qter,5,12q24,13,18 1p34pter,3p,3q26qter, 6,20 N Ct/RT?E?Ct A
4q13q21,8,9q22qter,16
005 1q,2p12pter 5q32qter,13q14q22 6p N E+Ct D
035 1p31pter,7p21pter,17p11qter,19 5,6q21qter,13q13qter 1q11q24,6p N E D
048 13q31qter,14,20p12pter 2q36qter,13q14q21 1q,6p N E+RT?Ct D
NAR group
001
b 1q,5p,13q31qter 6p N E A
008(R)
a 2p23,6p21.3pter NE A
012
a 2p,6p,18 N E (R) A
019
ab 2p23p24,6p,9q34,14q32,19,20p12pter Xp22 N E (L) A
LSRT (R)
040
a 1,2p16pter 6p N E A
045
a 2p22pter NE A
047 1q,2p13pter,6p,13,17q21qter 12p13,16q N E A
052 2p24pter NE A
029 1q,2p23pter,6q13p23,7q21qter, 2q31qter,3q,6q22qter,16q 2.1 EA
18q12pter,19q12pter,20q11pter
033
a 1q,2p23pter,13q22qter,15q14qter 16,17p 2.0 E (R) A
LSRT (L)
038 1q,2p23pter,2p15p21,6p,Xp11 14q32,16q 3.5 EA
009 13q12q31 2q12pter NE A
044 12q24 2q35qter,16q13q21 1q,2p12pter 2.3 EA
051 1q25qter,2,5p13pter,7p,7q31qter, 1p32pter,12p,16,19,Y 2p 2.5 EA
9p23pter,12q14q21,12q24,20q
026 7q34qter,9q34,14,17p13,17q25,19,20p12pter 3p25pter,13q33qter,16q 2p21p25 99.6 EA
050 1q,13q12qter 2q24q31,3q11q21,6q22,8p,14q32,20q13 2p12pter 41.0 **Ct+E A
054 1q25,7q22q34,13q21q32 6q14q21 2p22p24 38.1 EA
Gains (CGH ratio 41.2551.5) or ampliﬁcations (CGH ratio 41.5) of 2p or N-MYC (RQ–PCR copy no 52.0) are highlighted in bold. *Average ratio of N-MYC to reference
gene. N=normal copy number.
aBilateral case.
bPositive family history of Rb. Ct=chemotherapy. LSRT=lens sparing radiotherapy. E=enucleation. **Patient failed chemotherapy
and proceeded to enucleation. A=alive. D=dead.
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71. The Taqman
probe for N-MYC carried a 5' FAM reporter and a TAMRA
quencher (Perkin Elmer, Warrington, UK). N-MYC probe
sequence was 5'-(FAM)-ACAATAATTTTCTACCCCAGCGTGGT-
AGTCAATG-(TAMRA)-3', used at 100 nmol l
71. PCR ampliﬁca-
tion was performed as previously described (Goff et al, 2000).
Each assay included ‘no template’ control and standard curves using
placental DNA diluted over ﬁve logs. To ascertain N-MYC copy
number, the copy number of B2M (15q21-22), ALB (4q11-13),
MLL (11q23), AF10 (10p12) and REL (2p12-13) (reference genes)
was also investigated. For each tumour the ratio of N-MYC copy
number/ reference gene copy number was determined and a value
above two considered indicative of ampliﬁcation (Bieche et al,
1998). N-MYC copy number was deduced using a minimum of
three reference genes selected on the basis of the CGH results being
normal for those regions. All standard curves had a correlation coef-
ﬁcient of at least 0.99. The primer oligonucleotides were synthesized
by the Imperial Cancer Research Fund, Oligonucleotide Synthesis
Service.
RESULTS AND DISCUSSION
The RQ–PCR results are summarised in Table 2. Three tumours
showed greater than 10-fold increase in N-MYC copy number
(026, 050 and 054) at 100-, 41- and 38-fold respectively. Figure
1a represents the ampliﬁcation plot for N-MYC and B2M from
tumour 026 and a typical standard curve (B2M) is shown in
Figure 1b. Two of the three patients (026 and 054) were diag-
nosed at less than 12 months (7 and 3 months, respectively)
whilst the third patient (050) presented at 67 months. Contrary
to the ﬁndings by Mairal et al (2000) that tumours with ampliﬁ-
cation of N-MYC show mild differentiation, all three tumours
studied here were poorly differentiated. All three patients are alive
at 108 (026), 65 (050) and 54 (054) months post enucleation and
although the tumours were poorly differentiated, none of them
demonstrated either of the recognised adverse histological features,
namely deep choroidal or retrolaminar invasion of the optic
nerve. The four tumours reported by Mairal et al (2000) with
ampliﬁcation of N-MYC also lacked adverse histoprognostic risk
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Figure 1 (A) RQ–PCR results showing the ampliﬁcation plot for N-MYC and B2M (tumour 206). N-MYC:B2M copy number ratio=99.6. (B) Standard
Curve for B2M. Black dots represent standard log dilutions, grey dots represent test DNA. The correlation coefﬁcient for this standard curve was 0.998.
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copies of N-MYC with poor outcome. Despite gain of 6p being
a frequent CGH ﬁnding in Rb (34/49 tumours studied by
CGH, data not shown), all three tumours with high level ampli-
ﬁcation of N-MYC lacked gain of 6p. It has been suggested that
gain of 6p is associated with more aggressive tumours (Oliveros
and Yunis, 1995) and hence this lends further support to the
hypothesis that high N-MYC copy number is not an adverse
feature since these tumours also lacked gain of 6p. The three
patients who died following extra-ocular relapse (005, 035 and
048) showed no gain of N-MYC by RT–PCR and two also lacked
gain of 2p by CGH. Of those tumours with normal N-MYC copy
number by RQ–PCR, there were ﬁve tumours showing gain of
the entire 2p arm by CGH and 4 showing gain of just the 2p2
region. In all cases CGH suggested 0.5-fold increase (i.e. one addi-
tional copy) and hence RQ–PCR may not be reliable enough to
discern trisomy. The presence of any normal cells in the tumour
will also hinder the ability to detect trisomy but this would have
been applicable to the CGH experiments too. It is also possible
that other genes mapping within 2p2 e.g. Id2 may be the targets
for low level gain in this region. Id2 belongs to a family of Id
genes exerting an inhibitory effect on transcription by heterodi-
merising with basic helix–loop–helix proteins. Recently,
Lasorella et al (2002) demonstrated the correlation of Id2 and
N-MYC expression and suggested that Id2 overexpression in
neuroblastoma may be a better prognostic indicator than N-
MYC ampliﬁcation. Four tumours showing adverse histology did
show gain of N-MYC; in tumours 017, 08L and 041 the increase
was between 2–3-fold and in tumour 004 there was a 6.7-fold
increase.
In summary, molecular markers have allowed more precise
assessment of an individual patient’s prognosis in a number of
malignant diseases and, in particular, N-MYC copy number is an
important prognostic indicator in neuroblastoma and inﬂuences
management. In the retinoblastomas studied in this series, tumours
with ampliﬁcation of N-MYC copy number (430-fold) were not
associated with adverse histology or outcome, nor were they asso-
ciated with gain of 6p. Those tumours with adverse histology and
adverse outcome (death following metastasis) did not exhibit either
low or high copy number gain of N-MYC. The presence of multi-
ple copies of N-MYC in Rb does not, therefore, appear to predict a
poor clinical outcome.
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